Thermo Fisher Scientific Inc, a company that serves science, announced on Monday that it has launched the Thermo Scientific Hypulse Surface Analysis System, a next-generation instrument for X-ray photoelectron spectroscopy (XPS) depth-profiling.
Designed to accelerate materials research, the Hypulse system enables deeper, more accurate analysis of surfaces to support industries from energy storage and fire protection to medical implants. In healthcare applications, the technology could inform the development of coatings that improve biocompatibility, durability and infection resistance.
The system is distinguished by its use of femtosecond laser technology for material removal, allowing faster data collection, greater depth penetration and improved preservation of sample accuracy.
Thermo Fisher said the Hypulse platform represents a step forward in creating better materials and enhancing industrial applications, advancing its mission to enable customers to make the world healthier, cleaner and safer.
Genetic Analysis AS launches new microbiome diagnostic tool for the global research market
BioArctic secures Australian approval for Alzheimer's drug Leqembi
Sanofi's SAR446268 receives FDA fast track designation for myotonic dystrophy type 1
New Study Shows Poor Inventory Practices Are Restricting Growth for HME|DME Providers
MavriX Bio receives Fast Track designation from FDA for MVX-220
GC Biopharma submits IND application in South Korea for Phase 1 trial of COVID-19 vaccine candidate
Sichuan Kelun-Biotech Biopharmaceutical NDA for A400 accepted for review in China
Akeso showcasing late-breaking abstract from ivonescimab study at ESMO
Neurocrine Biosciences reports positive phase 2 results for osavampator in major depressive disorder
Tempus secures FDA clearance for RNA-based xR IVD diagnostic device
Thermo Fisher unveils Hypulse System for advanced surface analysis
Regenerative Agriculture Pioneer Bob Jones to Deliver Keynote at Metabolic Health Day Conference
N4 Pharma advances RNA delivery breakthrough with SRI collaboration
Genentech reports positive Phase III results for giredestrant in ER-positive advanced breast cancer